Business Description
LAVA Therapeutics NV
ISIN : NL0015000AG6
Description
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 14.08 | |||||
| Equity-to-Asset | 0.47 | |||||
| Debt-to-Equity | 0.14 | |||||
| Debt-to-EBITDA | -0.25 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -1.55 | |||||
| Beneish M-Score | -3.59 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 19.6 | |||||
| 3-Year EBITDA Growth Rate | -36.2 | |||||
| 3-Year EPS without NRI Growth Rate | -36 | |||||
| 3-Year FCF Growth Rate | -56.6 | |||||
| 3-Year Book Growth Rate | 86.3 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 55.96 | |||||
| 9-Day RSI | 59.12 | |||||
| 14-Day RSI | 58.73 | |||||
| 6-1 Month Momentum % | -42.56 | |||||
| 12-1 Month Momentum % | 39.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.39 | |||||
| Quick Ratio | 6.39 | |||||
| Cash Ratio | 6.15 | |||||
| Days Sales Outstanding | 77.45 | |||||
| Days Payable | 11793.51 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.2 | |||||
| Shareholder Yield % | -0.39 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 97.78 | |||||
| Operating Margin % | -371.48 | |||||
| Net Margin % | -326.89 | |||||
| FCF Margin % | -366.14 | |||||
| ROE % | -45.94 | |||||
| ROA % | -22.96 | |||||
| ROIC % | -319.85 | |||||
| 3-Year ROIIC % | -1781.84 | |||||
| ROC (Joel Greenblatt) % | -982.94 | |||||
| ROCE % | -29.1 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 6.96 | |||||
| PB Ratio | 1.18 | |||||
| Price-to-Tangible-Book | 1.09 | |||||
| EV-to-EBIT | 1.17 | |||||
| EV-to-EBITDA | 1.23 | |||||
| EV-to-Revenue | -4.07 | |||||
| EV-to-Forward-Revenue | 2.05 | |||||
| EV-to-FCF | 1.11 | |||||
| Price-to-Net-Current-Asset-Value | 1.15 | |||||
| Price-to-Net-Cash | 1.25 | |||||
| Earnings Yield (Greenblatt) % | 85.47 | |||||
| FCF Yield % | -53.65 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:LVTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
LAVA Therapeutics NV Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 7.398 | ||
| EPS (TTM) ($) | -0.89 | ||
| Beta | 0.61 | ||
| Volatility % | 116.98 | ||
| 14-Day RSI | 58.73 | ||
| 14-Day ATR ($) | 0.114891 | ||
| 20-Day SMA ($) | 1.75028 | ||
| 12-1 Month Momentum % | 39.5 | ||
| 52-Week Range ($) | 1.16 - 6.47 | ||
| Shares Outstanding (Mil) | 26.3 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
LAVA Therapeutics NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
LAVA Therapeutics NV Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
LAVA Therapeutics NV Frequently Asked Questions
What is LAVA Therapeutics NV(LVTX)'s stock price today?
The current price of LVTX is $1.78. The 52 week high of LVTX is $6.47 and 52 week low is $1.16.
When is next earnings date of LAVA Therapeutics NV(LVTX)?
The next earnings date of LAVA Therapeutics NV(LVTX) is 2024-11-15 Est..
Does LAVA Therapeutics NV(LVTX) pay dividends? If so, how much?
LAVA Therapeutics NV(LVTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers